Statistical issues in first-in-human studies on BIA 10-2474: neglected comparison of protocol against practice

Sheila M. Bird, Rosemary A. Bailey, Andrew P. Grieve, Stephen Senn

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
2 Downloads (Pure)

Abstract

By setting the regulatory-approved protocol for a suite of first-in-human studies on BIA 10-2474 against the subsequent French investigations, we highlight six key design and statistical issues which reinforce recommendations by a Royal Statistical Society Working Party which were made in the aftermath of cytokine release storm in six healthy volunteers in the UK in 2006.
The 6 issues are dose determination, availability of pharmacokinetic results, dosing interval, stopping rules, appraisal by safety committee, and clear algorithm required if combining approvals for single and multiple ascending dose studies.
Original languageEnglish
Pages (from-to)100-106
Number of pages7
JournalPharmaceutical Statistics
Volume16
Issue number2
Early online date16 Feb 2017
DOIs
Publication statusPublished - 15 Mar 2017

Keywords

  • BIAL 10-2474
  • Protocol
  • Design
  • Statistical issues
  • Combined approvals

Fingerprint

Dive into the research topics of 'Statistical issues in first-in-human studies on BIA 10-2474: neglected comparison of protocol against practice'. Together they form a unique fingerprint.

Cite this